Therapeutic strategies targeting cancer stem cells

Go J. Yoshida, Hideyuki Saya

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Cancer stem cells (CSCs) are undifferentiated cancer cells with a high tumorigenic activity, the ability to undergo self-renewal, and a multilineage differentiation potential. Cancer stem cells are responsible for the development of tumor cell heterogeneity, a key feature for resistance to anticancer treatments including conventional chemotherapy, radiation therapy, and molecularly targeted therapy. Furthermore, minimal residual disease, the major cause of cancer recurrence and metastasis, is enriched in CSCs. Cancer stem cells also possess the property of "robustness", which encompasses several characteristics including a slow cell cycle, the ability to detoxify or mediate the efflux of cytotoxic agents, resistance to oxidative stress, and a rapid response to DNA damage, all of which contribute to the development of therapeutic resistance. The identification of mechanisms underlying such characteristics and the development of novel approaches to target them will be required for the therapeutic elimination of CSCs and the complete eradication of tumors. In this review, we focus on two prospective therapeutic approaches that target CSCs with the aim of disrupting their quiescence or redox defense capability.

Original languageEnglish
Pages (from-to)5-11
Number of pages7
JournalCancer Science
Volume107
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Neoplastic Stem Cells
Neoplasms
Therapeutics
Cytotoxins
Residual Neoplasm
DNA Damage
Oxidation-Reduction
Cell Cycle
Oxidative Stress
Radiotherapy
Neoplasm Metastasis
Recurrence
Drug Therapy

Keywords

  • CD44
  • Fbw7
  • Intratumoral heterogeneity
  • Niche
  • Plasticity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapeutic strategies targeting cancer stem cells. / Yoshida, Go J.; Saya, Hideyuki.

In: Cancer Science, Vol. 107, No. 1, 01.01.2016, p. 5-11.

Research output: Contribution to journalArticle

Yoshida, Go J. ; Saya, Hideyuki. / Therapeutic strategies targeting cancer stem cells. In: Cancer Science. 2016 ; Vol. 107, No. 1. pp. 5-11.
@article{8a27d69ca1e848c8899e5e0c9a37468d,
title = "Therapeutic strategies targeting cancer stem cells",
abstract = "Cancer stem cells (CSCs) are undifferentiated cancer cells with a high tumorigenic activity, the ability to undergo self-renewal, and a multilineage differentiation potential. Cancer stem cells are responsible for the development of tumor cell heterogeneity, a key feature for resistance to anticancer treatments including conventional chemotherapy, radiation therapy, and molecularly targeted therapy. Furthermore, minimal residual disease, the major cause of cancer recurrence and metastasis, is enriched in CSCs. Cancer stem cells also possess the property of {"}robustness{"}, which encompasses several characteristics including a slow cell cycle, the ability to detoxify or mediate the efflux of cytotoxic agents, resistance to oxidative stress, and a rapid response to DNA damage, all of which contribute to the development of therapeutic resistance. The identification of mechanisms underlying such characteristics and the development of novel approaches to target them will be required for the therapeutic elimination of CSCs and the complete eradication of tumors. In this review, we focus on two prospective therapeutic approaches that target CSCs with the aim of disrupting their quiescence or redox defense capability.",
keywords = "CD44, Fbw7, Intratumoral heterogeneity, Niche, Plasticity",
author = "Yoshida, {Go J.} and Hideyuki Saya",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/cas.12817",
language = "English",
volume = "107",
pages = "5--11",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Therapeutic strategies targeting cancer stem cells

AU - Yoshida, Go J.

AU - Saya, Hideyuki

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cancer stem cells (CSCs) are undifferentiated cancer cells with a high tumorigenic activity, the ability to undergo self-renewal, and a multilineage differentiation potential. Cancer stem cells are responsible for the development of tumor cell heterogeneity, a key feature for resistance to anticancer treatments including conventional chemotherapy, radiation therapy, and molecularly targeted therapy. Furthermore, minimal residual disease, the major cause of cancer recurrence and metastasis, is enriched in CSCs. Cancer stem cells also possess the property of "robustness", which encompasses several characteristics including a slow cell cycle, the ability to detoxify or mediate the efflux of cytotoxic agents, resistance to oxidative stress, and a rapid response to DNA damage, all of which contribute to the development of therapeutic resistance. The identification of mechanisms underlying such characteristics and the development of novel approaches to target them will be required for the therapeutic elimination of CSCs and the complete eradication of tumors. In this review, we focus on two prospective therapeutic approaches that target CSCs with the aim of disrupting their quiescence or redox defense capability.

AB - Cancer stem cells (CSCs) are undifferentiated cancer cells with a high tumorigenic activity, the ability to undergo self-renewal, and a multilineage differentiation potential. Cancer stem cells are responsible for the development of tumor cell heterogeneity, a key feature for resistance to anticancer treatments including conventional chemotherapy, radiation therapy, and molecularly targeted therapy. Furthermore, minimal residual disease, the major cause of cancer recurrence and metastasis, is enriched in CSCs. Cancer stem cells also possess the property of "robustness", which encompasses several characteristics including a slow cell cycle, the ability to detoxify or mediate the efflux of cytotoxic agents, resistance to oxidative stress, and a rapid response to DNA damage, all of which contribute to the development of therapeutic resistance. The identification of mechanisms underlying such characteristics and the development of novel approaches to target them will be required for the therapeutic elimination of CSCs and the complete eradication of tumors. In this review, we focus on two prospective therapeutic approaches that target CSCs with the aim of disrupting their quiescence or redox defense capability.

KW - CD44

KW - Fbw7

KW - Intratumoral heterogeneity

KW - Niche

KW - Plasticity

UR - http://www.scopus.com/inward/record.url?scp=84956579802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956579802&partnerID=8YFLogxK

U2 - 10.1111/cas.12817

DO - 10.1111/cas.12817

M3 - Article

C2 - 26362755

AN - SCOPUS:84956579802

VL - 107

SP - 5

EP - 11

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -